- Previous Close
82.28 - Open
81.86 - Bid 79.79 x 400
- Ask 80.14 x 400
- Day's Range
79.32 - 82.35 - 52 Week Range
79.30 - 156.66 - Volume
1,526,437 - Avg. Volume
2,538,501 - Market Cap (intraday)
12.672B - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-7.69 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
130.64
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
www.illumina.com8,970
Full Time Employees
December 29
Fiscal Year Ends
Sector
Industry
Recent News: ILMN
View MorePerformance Overview: ILMN
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILMN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILMN
View MoreValuation Measures
Market Cap
12.67B
Enterprise Value
14.07B
Trailing P/E
--
Forward P/E
17.76
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.91
Price/Book (mrq)
5.34
Enterprise Value/Revenue
3.22
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.97%
Return on Assets (ttm)
2.64%
Return on Equity (ttm)
-30.13%
Revenue (ttm)
4.37B
Net Income Avi to Common (ttm)
-1.22B
Diluted EPS (ttm)
-7.69
Balance Sheet and Cash Flow
Total Cash (mrq)
1.22B
Total Debt/Equity (mrq)
110.49%
Levered Free Cash Flow (ttm)
265.38M